China’s Antengene raises $120m Series B round
Antengene Corporation, a Chinese biopharmaceutical company focused on oncology drugs and therapies, has raised $120 million in a Series B round led by Boyu Capital and FountainVest Partners.
Other participants include Celgene Corporation, WuXi Corporate Venture Fund, Taikang Insurance Group, and existing investors Qiming Venture Partners and TF Capital. The company raised a $21 million Series...
More on Greater China
Latest News
Philippines PE: Power dynamics
A virtually impenetrable middle market under the control of incumbent conglomerates is the least governable of the systemic obstacles facing private equity hopefuls in the Philippines
GGV backs Singapore dental 3D printing company
GGV Capital has joined a group of investors in a venture round of undisclosed size for Structo, a Singapore-based 3D printing company focused on the dental industry.
Ant Financial invests $92m in Chinese e-signature provider
TSign – a China-based electronic signature service provider – has received RMB650 million ($92 million) in Series C funding led by Alibaba Group affiliate Ant Financial. Other investors include Gobi Partners and Eminence Ventures.